
|Articles|January 1, 2002
TNF blockers control psoriatic arthritis
San Francisco - Both tumor necrosis factor (TNF) blockers etanercept and infliximab continue to play an emerging role in the treatment of psoriatic arthritis (PsA), according to two new studies presented at the American College of Rheumatology annual meeting here.
Advertisement
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement


















